-transparent.png){kind=logo}
A new anticoagulant, recombinant hirudin, was given to healthy volunteers (5 per test dose) in single intravenous doses of 0.01, 0.02, 0.04, 0.07 and 0.1 mg/kg to study its anticoagulant effects, how it was tolerated and its pharmacokinetics. Hirudin proved to be a potent anticoagulant with important effects on thrombin (increase in thrombin time and partial thromboplastin time). The maximum pharmacodynamic effect was achieved with the 0.07 mg/kg dose, and upwards. All doses of the compound were tolerated without side-effects. The mean elimination half-life is about 1 hour. Mean total clearance and volume of distribution are approximately 190 ml/min and 14 l, respectively. Hirudin obeys first-order pharmacokinetics.
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
February 1998,
Kidney international. Supplement,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
October 2002,
Seminars in thrombosis and hemostasis,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
January 1989,
Folia haematologica (Leipzig, Germany : 1928),
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
January 1991,
Haemostasis,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
April 1991,
Seminars in thrombosis and hemostasis,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
February 1991,
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
December 2000,
Anesthesiology,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
September 1995,
Current opinion in hematology,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
June 1994,
Kidney international,
B H Meyer, and
H G Luus, and
F O Müller, and
P N Badenhorst, and
H J Röthig
December 2021,
Thrombosis research,
